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Abstract  
The present study was designed to assess the role of 5-HT2A/2C 
receptors in the acute and repeated effect of clozapine and 
olanzapine in a rat conditioned avoidance response model, a 
validated model of antipsychotic activity. Male Sprague–Daw-
ley rats that were previously treated with either phencyclidine 
(0.5–2.0 mg/kg, sc), amphetamine (1.25–5.0 mg/kg, sc), or sa-
line and tested in a prepulse inhibition of acoustic startle study 
were used. They were first trained to acquire avoidance re-
sponse to a white noise (CS1) and a pure tone (CS2) that dif-
fered in their ability to predict the occurrence of footshock. 
Those who acquired avoidance response were administered 
with clozapine (10.0 mg/kg, sc) or olanzapine (1.0 mg/kg, sc) 
together with either saline or 1-2,5-dimethoxy-4-iodo-amphet-
amine (DOI, a selective 5-HT2A/2C agonist, 1.0 or 2.5 mg/kg, 
sc), and their conditioned avoidance responses were tested for 
four consecutive days. After two drug-free retraining days, the 
long-term repeated effect was assessed in a challenge test dur-
ing which all rats were injected with a low dose of clozapine 
(5 mg/kg, sc) or olanzapine (0.5 mg/kg). Results show that 
pretreatment of DOI dose-dependently reversed the acute dis-
ruptive effect of clozapine on both CS1 and CS2 avoidance re-
sponses, whereas it had little effect in reversing the acute ef-
fect of olanzapine. On the challenge test, pretreatment of DOI 
did not alter the clozapine-induced tolerance or the olanzap-
ine-induced sensitization effect. These results confirmed our 
previous findings and suggest that clozapine, but not olanzap-
ine, acts on through 5-HT2A/2C receptors to achieve its acute 
avoidance disruptive effect and likely its therapeutic effects. 
The long-term clozapine tolerance and olanzapine sensitiza-
tion effects appear to be mediated by non-5-HT2A/2C receptors. 
Keywords:  Clozapine,  Olanzapine,  2,5-Dimethoxy-4-iodo-
amphetamine, Repeated antipsychotic treatment, D2/3 recep-
tor, 5-HT2A/2C receptor, Conditioned avoidance response, Sen-
sitization, Tolerance 
Introduction
In behavioral pharmacology, the conditioned avoid-
ance response (CAR) model is routinely used as a pre-
clinical test for antipsychotic activity (Arnt 1982). In 
a typical experiment, a rat is placed in a two-compart-
ment shuttle box and presented with a neutral condi-
tioned stimulus (CS) such as a light or tone, followed 
by an aversive unconditioned stimulus (US), such as a 
footshock. The animal may escape the US by running 
from one compartment to the other. However, after sev-
eral presentations of the CS–US pairing, the animal typ-
ically runs during the CS and before the onset of the US, 
thereby avoiding the US altogether. Rats acutely treated 
with low doses (non-cataleptic) of antipsychotic drugs 
(APDs) often fail to acquire or perform avoidance re-
sponses to the CS, whereas their escape responses to the 
US are less affected (Ader and Clink 1957; Wadenberg 
and Hicks 1999). This feature is shared by all clinically 
approved antipsychotic drugs, but not by anxiolytics or 
antidepressants (Mead et al. 2008; Sun et al. 2010). 
In recent years, we have expanded the use of this 
model to study the behavioral and neurochemical mech-
anisms of action of antipsychotic drugs (Li et al. 2007, 
2009a, b, 2010; Mead and Li 2010). We also focus on the 
long-term (repeated) effect of antipsychotic treatment. 
One interesting finding comes from our recent study (Li 
et al. 2010). In this study, we compared the acute and re-
peated effects of clozapine and olanzapine, two atypical 
antipsychotic drugs. We found that although acute ad-
ministration of both drugs produces a similar disruptive 
effect on conditioned avoidance responding, repeated 
administration of clozapine produces a tolerance-like ef-
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fect (i.e. a gradual decrease in disrupting avoidance over 
time), whereas repeated administration of olanzapine 
produces a sensitization-like effect (a gradual increase 
in disrupting avoidance over time). We also showed 
that pretreatment of 1-2,5-dimethoxy-4-iodo-amphet-
amine (DOI, a selective 5-HT2A/2C agonist, 2.5 mg/kg, 
sc), but not quinpirole (a selective dopamine D2/3 ago-
nist, 1.0 mg/kg, sc), attenuated the acute clozapine-in-
duced disruption of avoidance responding, whereas 
pretreatment of quinpirole, but not DOI, attenuated that 
effect of olanzapine. On the repeated effects, pretreat-
ment of DOI had no effect on either clozapine-induced 
tolerance or olanzapine-induced sensitization. In con-
trast, pretreatment of quinpirole attenuated the poten-
tiated disruption of olanzapine, but enhanced the tol-
erance-like effect of clozapine. Based on these findings 
on doubly dissociated receptor mechanisms, we suggest 
that acute clozapine disrupts avoidance response pri-
marily by blocking 5-HT2A/2C receptors, whereas acute 
olanzapine appears to exert its disruptive effect primar-
ily by blocking dopamine D2 receptors. Both clozap-
ine-induced tolerance and olanzapine-induced sensiti-
zation are likely mediated by D2/3 receptor, but not by 
5-HT2A/2C receptor. 
Because olanzapine, like clozapine, also possesses 
a potent antagonism on the 5-HT2A/2C receptor in ad-
dition to a relatively weak antagonism on D2 receptor 
(Meltzer et al. 2003), it is thus surprising that 5-HT2A/2C 
receptor is not found to be involved in the acute effect 
of olanzapine and it does not seem to play little role 
in the repeated effects of both drugs. These behavioral 
and neurochemical similarities and differences be-
tween the acute and repeated effects of clozapine and 
olanzapine warrant further investigation. The pres-
ent study was designed to further assess the role of the 
5-HT2A/2C receptor in the acute and repeated effect of 
clozapine and olanzapine to ensure that our previous 
findings are not artifacts and can be generalized to dif-
ferent animals and across different testing conditions. 
In the present study, we used heterogeneous groups of 
animals that had prior experience with either amphet-
amine, phencyclidine (PCP), or saline, as opposed to 
normal drug-naïve animals. These amphetamine- and 
PCP-pretreated rats had been shown to exhibit a def-
icit in the prepulse inhibition (PPI) of acoustic startle 
(Li et al. 2011), one of the most studied cognitive def-
icits associated with schizophrenia. Thus, they could 
be considered as putative “schizophrenic-like” animals 
(Geyer et al. 2001; Russig et al. 2003). In addition, we 
used a modified CAR paradigm involving two types of 
CS (CS1: a white noise and CS2: a pure tone), as op-
posed to just the CS1 used in our previous work (Li 
et al. 2010). We created these two types of CS signals 
that varied in their motivational salience (e.g. ability to 
elicit avoidance) and ability to predict the occurrence 
of an US footshock. This was achieved by pairing the 
CS1 with the US in every CS1 trial while pairing the 
CS2 with the US in only half of the CS2 trials if the rats 
failed to respond. This novel paradigm provides an ad-
ditional measure of antipsychotic drug treatment on 
avoidance responding. We have used this paradigm to 
examine the behavioral mechanisms of antipsychotic 
action (Li et al. 2009b; Zhang et al. 2011) and aberrant 
behavioral responding in animal models of schizo-
phrenia (Li et al. 2008; Chen et al. 2011). 
Materials and methods
Animals
Subjects were male Sprague–Dawley rats (226–250 g 
upon arrival) purchased from Charles River Inc. (Por-
tage, MI). They had been used in a separate study in 
which they were repeatedly treated with either amphet-
amine (1.25–5.0 mg/kg), PCP (0.5–2.0 mg/kg) or vehi-
cle and tested for PPI of acoustic startle response once 
daily for six consecutive days (Li et al. 2011). None of 
them had any antipsychotic drug experience prior to 
this study and there was at least a 2-week interval be-
tween the last amphetamine or PCP experience and the 
first antipsychotic treatment. Rats were housed two per 
cage, in 48.3 cm × 26.7 cm × 20.3 cm transparent poly-
carbonate cages under 12-h light/dark conditions (light 
on between 6:30 a.m. and 6:30 p.m.). Room temperature 
was maintained at 22 ± 1°C with a relative humidity of 
50–60%. Food and water were available ad libitum. An-
imals were allowed at least 1 week of habituation to 
the animal facility before being used in experiments. 
All procedures were approved by the Institutional An-
imal Care and Use Committee at the University of 
Nebraska–Lincoln. 
Two-way avoidance conditioning apparatus
Eight identical two-way shuttle boxes custom de-
signed and manufactured by Med Associates (St. 
Albans, VT) were used. Each box was housed in 
a ventilated, sound-insulated isolation cubicle 
(96.52 cm W × 35.56 cm D × 63.5 cm H). Each box was 
64 cm long, 30 cm high (from grid floor), and 24 cm 
wide, and was divided into two equal-sized compart-
ments by a partition with an arch style doorway (15 cm 
high × 9 cm wide at base). A barrier (4 cm high) was 
placed between the two compartments, so the rats had 
to jump from one compartment to the other. The grid 
floor consisted of 40 stainless-steel rods with a diam-
eter of 0.48 cm, spaced 1.6 cm apart center to center, 
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through which a scrambled footshock (US, 0.8 mA, 
maximum duration 5 s) was delivered by a constant 
current shock generator (Model ENV-410B) and scram-
bler (Model ENV-412). Illumination was provided by 
two houselights mounted at the top of each compart-
ment. The conditioned stimuli (either a 76 dB white 
noise CS1 or a 85 dB 2,800 Hz pure tone CS2) were pro-
duced by a speaker (ENV 224 AMX) mounted on the 
ceiling of the cubicle, centered above the shuttle box. 
Background noise (approximately 74 dB) was provided 
by a ventilation fan affixed at the top corner of each 
isolation cubicle. All training and testing procedures 
were controlled by Med Associates programs running 
on a computer. 
Drugs
Clozapine (CLZ) and olanzapine (OLZ) (gifts from 
NIMH drug supply program) were dissolved in 1.0% 
glacial acetic acid in distilled water. DOI (RBI-Sigma, 
Natick, MA) was dissolved in 0.9% saline. All drugs 
were administered subcutaneously in a volume of 
1.0 ml/kg body weight. Choices of drug doses for CLZ 
and OLZ were based on our previous studies show-
ing that at the chosen doses; both produce a reliable 
and comparable disruption of avoidance responding 
(Li et al. 2004a, 2009a, b, 2010; Mead and Li 2010), and 
they give rise to clinical levels of striatal D2 occupancy 
(50–80%) at these doses (Kapur et al. 2003). The doses 
of DOI were chosen based on our recent work showing 
that DOI at 2.5 mg/kg reversed the avoidance-disrup-
tive effect (Li et al. 2010) and the maternal-disruptive ef-
fect of clozapine (Zhao and Li 2009). Previous work also 
showed that DOI produces maximal behavioral effects 
between 2 and 3 mg/kg (Schreiber et al. 1995; Granoff 
and Ashby 1998; Halberstadt et al. 2009). 
Experiment 1: Effects of DOI pretreatment on 
clozapine-induced CS1 and CS2 avoidance disruption
Sixty rats previously used in the PPI study (Li et al. 
2011) were used in this experiment. In that study, one 
group of rats (n = 12) was repeatedly injected with sa-
line and tested for PPI daily for six consecutive days. 
The second group (n = 12) was repeatedly injected with 
4.0 mg/kg amphetamine for six consecutive days. The 
third group was injected with 1.25 mg/kg amphet-
amine on day 1–2, 2.5 mg/kg on day 3–4, and 5.0 mg/
kg on day 5–6. The fourth group was repeatedly injected 
with 2.0 mg/kg phencyclidine throughout the six con-
secutive days. Last, the fifth group was injected with 
0.5 mg/kg phencyclidine on day 1–2, 1.0 mg/kg on day 
3–4 and 2.0 mg/kg on day 5–6. 
Thirteen days after the last PPI test, all rats were 
trained in the modified two-way avoidance condition-
ing task for a total of ten sessions over a 2-week pe-
riod. Each training session consisted of 30 trials. Ten 
trials (CS1 trials) used a 10-s 76-dB white noise as the 
CS with its termination immediately followed by the 
shock (0.8 mA, maximum duration 5 s) if the rats did 
not make an avoidance response. The remaining 20 
trials (CS2 trials) used a pure tone (10 s, 2,800 kHz, 
85 dB) as the CS. In ten CS2 trials, the CS2 was fol-
lowed by the shock if the rat failed to respond to the 
CS2, whereas, in another ten trials, there was no shock 
following the CS2. The ten CS1 trials were randomly 
intermixed with the 20 CS2 trials. During each trial, if 
a subject moved from one compartment into the other 
within the 10-s CS presentation, that CS was immedi-
ately terminated, the shock was prevented, and this 
shuttling response was recorded as avoidance (termed 
CS1 avoidance or CS2 avoidance). If the rat remained 
in the same compartment for more than 10 s and made 
a crossing upon receiving the footshock, this response 
was recorded as escape. If the rat did not respond dur-
ing the entire 5-s presentation of the shock, the trial 
was terminated and escape failure was recorded. At 
the end of training session, 46 rats had reached train-
ing criterion (≥7 CS1 avoidances and at least one CS2 
avoidance in the last two training sessions: mean num-
ber of CS1 avoidance = 9.39 + 0.13 and mean number 
of CS2 avoidance = 13.09 + 0.59). We did not find any 
prior amphetamine or PCP treatment effect on the ac-
quisition of CS1 avoidance (F(4, 55) = 1.131, p = 0.351) 
or CS2 avoidance (F(4, 55) = 1.592, p = 0.189). The well-
trained rats were then randomly assigned to one of 
four groups: VEH + VEH (n = 11, saline + sterile wa-
ter), VEH + CLZ (n = 12), DOI−1.0 mg/kg + CLZ 
(n = 12), and DOI−2.5 mg/kg + CLZ (n = 11), and 
tested daily under the CS-only condition (no shock, 
ten CS1 trials, and 20 CS2 trials) for four consecutive 
days. During each test, rats were first pretreated with 
DOI 1.0 mg/kg, 2.5 mg/kg (sc) or saline followed by 
an injection of sterile water (VEH), or CLZ 10.0 mg/
kg (sc) 10 min later. Thirty minutes after the second in-
jection, rats were placed in the CAR boxes and tested. 
One day after the last drug test, all rats were tested 
drug-free for one session under the CS-only (no shock) 
condition and retrained for one session under the CS–
US condition to bring their avoidance back to the pre-
drug level. A final drug challenge test was conducted 
24 h after the retraining session to assess the long-term 
effect of repeated antipsychotic treatment on avoid-
ance. During the test, all rats were injected with CLZ 
5.0 mg/kg and tested 1 h later in the same CAR proce-
dure as used in the drug testing phase. 
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Experiment 2: Effects of DOI pretreatment on 
olanzapine-induced CS1 and CS2 avoidance 
disruption
Thirty-six rats previously used in a PPI study were 
used in this experiment. Among them, 12 rats were re-
peatedly injected with saline and tested for PPI daily 
for six consecutive days. The second group (n = 12) 
was repeatedly injected with 0.5 mg/kg phencycli-
dine and the third group (n = 12) was repeatedly in-
jected with 1.0 mg/kg phencyclidine and tested for 
PPI daily for six consecutive days. Eighteen days after 
the last PPI test, rats were trained in the modified CAR 
task for ten sessions. At the end of the training phase, 
29 rats reached the training criterion (mean number of 
CS1 avoidance = 9.10 + 0.21 and mean number of CS2 
avoidance = 13.28 + 0.64), and their prior drug experi-
ence was not a factor in the acquisition of CS1 avoid-
ance (F(2, 33) = 1.551, p = 0.227) or CS2 avoidance (F(4, 
55) = 2.047, p = 0.145). Rats were then randomly as-
signed to the following three groups: VEH + VEH (sa-
line + sterile water, n = 9), VEH + OLZ (1.0 mg/kg, 
n = 10), and DOI−2.5 mg/kg + OLZ (1.0 mg/kg, n = 10), 
and were subjected to four sessions of drug testing, two 
sessions of drug-free testing/retraining and a final drug 
challenge test, following the exact same schedule as de-
scribed in “Experiment 1”. During the challenge test, all 
rats were injected with OLZ 0.5 mg/kg. 
Statistical analysis
Avoidance response data were expressed as 
mean ± SEM. Data on the four drug test sessions were 
analyzed using a repeated measures analysis of vari-
ance (ANOVA) with the between-subjects factor be-
ing the treatment (group) and the within-subjects fac-
tor being test session. Data for CS1 and CS2 avoidance 
were analyzed separately. Individual one-way ANO-
VAs followed by Tukey post hoc tests were used to de-
tect group differences on each drug test session and the 
final challenge session. A conventional two-tailed level 
of significance at the 5% level was used. 
Results
Experiment 1: effects of DOI pretreatment on clozapine-
induced CS1 and CS2 avoidance disruption
As can be seen in Figure 1, CLZ treatment suppressed 
CS1 and CS2 avoidance responses throughout the four 
drug test sessions. Pretreatment of DOI dose-depend-
ently reversed this effect of CLZ, and the DOI reversal 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
effect tended to decrease over the drug test sessions. Re-
peated-measures ANOVA on the number of CS1 avoid-
ance indicated a main effect of group, F(3, 42) = 24.008, 
p < 0.001, session, F(3, 126) = 6.318, p = 0.001, and a sig-
nificant interaction between group and test session, F(9, 
126) = 2.223, p = 0.025. For the CS2 avoidance, repeated 
measures ANOVA also revealed a main effect of group, 
F(3, 42) = 27.353, p < 0.001, session, F(3, 126) = 3.721, 
p = 0.013, and a significant interaction between group 
and test session, F(9, 126) = 1.978, p = 0.047. 
One-way ANOVAs followed by Tukey post hoc tests 
were used to examine group differences on each drug 
test session. On the CS1 avoidance, the VEH + CLZ 
group differed significantly from the VEH + VEH group 
on every drug day (all ps < 0.001). It also differed sig-
nificantly from the DOI−2.5 + CLZ group on day 1, 
p < 0.001 and day 2, p = 0.019, and differed significantly 
from the DOI−1.0 + CLZ group on day 1, p = 0.020. On 
the CS2 avoidance, the VEH + CLZ group differed sig-
nificantly from the vehicle group on every drug day (all 
ps < 0.001), but it only differed significantly from the 
DOI−2.5 + CLZ group on day 1, p < 0.003. Overall, re-
Figure 1. Effects of pretreatment of DOI on acute clozapine-
induced disruption of CS1 avoidance (a) and CS2 avoidance 
(b). Mean (+SEM) numbers of avoidance responses of the four 
groups of rats on the last CAR training day (pre-drug), four 
drug test days (Day 1 to Day 3), and two drug-free test days 
(drug-free CS-only and drug-free retraining). *p < 0.05 signifi-
cantly different from the VEH + VEH group; #p < 0.05 signifi-
cantly different from the VEH + CLZ group 
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sults from the drug test phase suggest that pretreatment 
of DOI dose-dependently reversed the CLZ-induced 
disruption of avoidance responding. This reversal effect 
was transient in nature and tended to diminish with re-
peated drug administration. It also showed a preferen-
tial action against CLZ disruption on CS1 avoidance (a 
response to a more salient stimulus) over CS2 avoidance 
(a response to a less salient stimulus). 
On the two drug-free sessions, there was no signifi-
cant group effect on either CS1 or CS2 avoidance (all 
ps > 0.412). However, on the drug challenge test during 
which all rats were acutely injected with CLZ at 5.0 mg/
kg (Figure 2), those that were previously treated with 
CLZ only (i.e. the VEH + CLZ rats) made more avoid-
ance responses than the vehicle rats treated with CLZ 
for the first time, indicating that prior CLZ treatment 
caused a decreased response to CLZ (a tolerance effect). 
One-way ANOVA revealed a main effect of group on 
the CS1 avoidance, F(3, 42) = 2.936, p = 0.044, and the 
CS2 avoidance F(3, 42) = 3.072, p = 0.038. Post-hoc tests 
indicated that the VEH + CLZ group differed signifi-
cantly from the VEH + VEH group on the CS2 avoid-
ance, p = 0.033. Pretreatment of DOI failed to alter the 
tolerance effect of repeated CLZ treatment, as there was 
no significant group difference between the VEH + CLZ 
group and the other two DOI pretreated groups (all 
ps > 0.0128). 
Experiment 2: effects of DOI pretreatment on 
olanzapine-induced CS1 and CS2 avoidance disruption
OLZ 1.0 mg/kg suppressed avoidance response on 
the first drug day and progressively enhanced its sup-
pression over the 4-day drug test period (Figure 3). The 
disruptive effect of OLZ did not seem to be affected 
by pretreatment of DOI. Repeated measures ANOVA 
on the number of CS1 avoidance indicated a main ef-
fect of group, F(2, 26) = 198.946, p < 0.001, session, F(3, 
78) = 7.238, p < 0.001, and a significant interaction be-
tween group and test session, F(6, 78) = 4.797, p < 0.001. 
For the CS2 avoidance, repeated measures ANOVA 
also revealed a main effect of group, F(2, 26) = 41.160, 
p < 0.001, session, F(3, 78) = 12.223, p < 0.001, and a sig-
nificant interaction between group and test session, F(6, 
78) = 2.620, p = 0.023. 
One-way ANOVAs followed by Tukey post hoc tests 
revealed that the two OLZ groups (i.e. VEH + OLZ and 
DOI−2.5 + OLZ) did not differ from each other on both 
the CS1 and CS2 avoidances (all ps > 0.498), but differed 
significantly from the VEH + VEH group on every drug 
day (all ps < 0.001), suggesting that pretreatment of DOI 
was ineffective in reversing the OLZ-induced disruption 
of avoidance responding. 
On the first drug-free test session, avoidance re-
sponses to CS1 and CS2 in the two OLZ-treated groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
recovered to some extent, but not to the level compa-
rable to that of the vehicle. There was a main effect of 
group for the CS1 avoidance, F(2, 26) = 10.554, p < 0.001, 
Figure 2. Effects of pretreatment of DOI on the repeated treat-
ment effect of clozapine on CS1 and CS2 avoidance responses. 
Data are mean (+SEM) numbers of avoidance responses on the 
challenge test day. Rats that were previously treated with dou-
ble vehicles, vehicle plus clozapine (10.0 mg/kg), or DOI (1.0 
or 2.5 mg/kg) plus clozapine (10.0 mg/kg) were challenged 
with clozapine (5.0 mg/kg). *p < 0.05 significantly different 
from the corresponding VEH + VEH group 
Figure 3. Effects of pretreatment of DOI on acute olanzapine-
induced disruption of CS1 avoidance (a) and CS2 avoidance 
(b). Mean (+SEM) numbers of avoidance responses of the four 
groups of rats on the last CAR training day (pre-drug), four 
drug test days (Day 1 to Day 3), and two drug-free test days 
(drug-free CS-only and drug-free retraining). *p < 0.05 signifi-
cantly different from the VEH + VEH group 
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and the CS2 avoidance, F(2, 26) = 4.738, p = 0.018. Post 
hoc tests showed that the VEH + OLZ group differed 
significantly from the VEH + VEH group on both types 
of avoidance (CS1: p < 0.001; CS2: p = 0.014), whereas 
the DOI−2.5 + OLZ group differed significantly from 
the VEH + VEH only on the CS1 avoidance (p = 0.016), 
but not on the CS2 avoidance (p = 0.146). On the sec-
ond drug-free retraining session, there was still a main 
effect of group for the CS2 avoidance, F(2, 26) = 4.462, 
p = 0.022. Post hoc tests showed that the VEH + OLZ 
group differed significantly from the VEH + VEH group 
on the CS2 avoidance (p = 0.026). 
On the drug challenge test during which all rats were 
acutely injected with OLZ at 0.5 mg/kg (Figure 4), rats 
previously treated with VEH + OLZ or DOI−2.5 + OLZ 
made fewer avoidances than the VEH + VEH rats, indi-
cating a strong sensitization-like effect of repeated OLZ 
treatment. One-way ANOVA revealed a main effect of 
group on the CS1 avoidance, F(2, 26) = 9.329, p = 0.001, 
and the CS2 avoidance F(2, 26) = 6.662, p = 0.005. Post-
hoc tests indicated that VEH + OLZ and DOI−2.5 + OLZ 
groups all differed significantly from the VEH + VEH 
group on the CS1 and CS2 avoidance (all ps < 0.013), 
suggesting that pretreatment of DOI failed to alter the 
long-term OLZ sensitization effect. 
Discussion
The present study further demonstrated an interest-
ing dissociated serotonin receptor mechanism under-
lying acute and repeated effects of clozapine and olan-
zapine on avoidance responding. On the acute effect 
side, we observed that pretreatment of DOI dose-de-
pendently reversed the clozapine-induced disruption, 
but had no effect on olanzapine-induced one. On the re-
peated effect side, we confirmed that repeated admin-
istration of clozapine produces a tolerance-like effect, 
whereas repeated administration of olanzapine pro-
duces a sensitization-like effect. Importantly, pretreat-
ment of DOI failed to alter both effects, suggesting that 
5-HT2A/2C receptor is not likely to be involved in the re-
peated effects of clozapine and olanzapine. 
The modified CAR paradigm was utilized in the 
present study to verify the receptor mechanisms of clo-
zapine and olanzapine as identified in our previous re-
port (Li et al. 2010) and to ensure our finding is not the 
artifact of any specific CAR setup. Despite the proce-
dural difference, we still observed that pretreatment of 
DOI dose-dependently reversed clozapine-induced dis-
ruption of avoidance but had no effect on olanzapine-
induced disruption, a finding consistent with our pre-
vious work (Li et al. 2010) in which we only used one 
avoidance response (CS1). We did notice two slightly 
different findings between the present clozapine study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
and the previous one. One is that the reversal effect of 
DOI 2.5 mg/kg seems stronger and more complete than 
the effect found in the previous study. For example, 
on the first drug day, the mean number of CS1 avoid-
ance in the DOI−2.5 + CLZ group was 86% of that in 
the VEH + VEH group in the present study, whereas it 
was only 46% of the VEH + VEH in the previous study. 
The second difference is that the DOI’s reversal effect 
diminished over the test sessions in the present study, 
whereas it remained stable in the previous study. These 
results suggest that although specific parameters used 
in a CAR procedure may not be critical in revealing the 
neuroreceptor mechanisms of action of antipsychotic 
drugs, they could influence the direction and magni-
tude of the behavioral effects of drugs, a phenomenon 
best known as the “rate-dependent drug effects” (Dews 
1976; Spealman et al. 1983; Barrett 2002; McMillan and 
Katz 2002; Barrett and Bergman 2008). The present find-
ing, together with our previous maternal behavior stud-
ies in which we showed that pretreatment of DOI, but 
not quinpirole, dose-dependently reversed the clozap-
ine-induced disruption of rat maternal behavior (Zhao 
and Li 2009, 2010), provides a strong support that clo-
zapine achieves its behavioral effects mainly by block-
ing 5-HT2A/2C receptors. 
Because olanzapine, like clozapine, has a potent antag-
onist action on 5-HT2A/2C receptors, it is somewhat sur-
prising to see this dissociated DOI effect on these drugs. 
However, it should be noted that olanzapine has a much 
lower 5-HT2A/2C affinity, but a much higher D2 receptor 
affinity than clozapine (Meltzer et al. 2003). Furthermore, 
olanzapine has a slower dissociation rate (k off value) 
from the D2 receptor than clozapine (Kapur and Seeman 
Figure 4. Effects of pretreatment of DOI on the repeated 
treatment effect of olanzapine on CS1 and CS2 avoidance re-
sponses. Data are mean (+SEM) numbers of avoidance re-
sponses on the challenge test day. Rats that were previously 
treated with double vehicles, vehicle plus olanzapine (1.0 mg/
kg), or DOI (2.5 mg/kg) plus olanzapine (1.0 mg/kg) were 
challenged with olanzapine (0.5 mg/kg). *p < 0.05 significantly 
different from the corresponding VEH + VEH group 
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2001). More importantly, its D2 receptor occupancy pre-
dicts its clinical effect better than its 5-HT2A/2C receptor 
occupancy (Kapur et al. 1999, 2000). These differences 
in molecular mechanisms of action may explain the dif-
ferences between olanzapine and clozapine in response 
to the DOI pretreatment. Because olanzapine’s D2 occu-
pancy correlates well with its disruptive effect on avoid-
ance response (Wadenberg et al. 2001; Olsen et al. 2008), 
it is thus likely that olanzapine’s avoidance disruptive ef-
fect is mainly mediated by its action on D2 receptor but 
not on 5-HT2A/2C receptor. Our previous finding that pre-
treatment of quinpirole, a selective dopamine D2/3 ago-
nist attenuates the acute olanzapine-induced disruption 
of avoidance response is consistent with this hypothe-
sis. The lack of involvement of 5-HT2A/2C receptors in the 
avoidance-disruptive effect of olanzapine is also consis-
tent with human brain imaging work suggesting that for 
olanzapine, D2 receptor occupancy alone can explain its 
antipsychotic effect (Kapur et al. 1999). 
Because clozapine has a dual action on both 5-HT2A 
and 5-HT2C receptors, and DOI is nonselective for 
5-HT2A versus 5-HT2C receptors, it is not certain which 
serotonin receptor is responsible for DOI’s reversal ef-
fect and the avoidance disruptive effect of clozapine. As 
we have discussed earlier (Li et al. 2010), we speculate 
that the 5-HT2A, but not 5-HT2C receptor, may be more 
important. This idea is supported by the findings that 
selective 5-HT2C receptor agonists are generally ineffec-
tive in counteracting clozapine (Ichikawa et al. 2001), 
and many behavioral and molecular effects of DOI are 
found to be mediated by its antagonism on 5-HT2A re-
ceptors, and not on 5-HT2C receptors (Schreiber et al. 
1995; Sipes and Geyer 1995, 1997; Smith et al. 2003; Hal-
berstadt et al. 2009). Future work using more selective 
5-HT2A and 5-HT2C receptor agonists may help deter-
mine the relative contribution of these two serotonin re-
ceptor subtypes in the mediation of the avoidance dis-
ruptive effect of clozapine. Clozapine has high affinity 
for adrenergic α1 receptor, muscarinic M1 receptor, and 
histamine H1 receptor and moderate affinity for the D4 
and 5-HT6 receptors, its actions on these receptors may 
also contribute to its avoidance-disruptive effect. 
In our previous study, we have used a similar mod-
ified CAR paradigm to examine the motivational sa-
lience attenuation action of antipsychotic treatment (Li 
et al. 2009b; Zhang et al. 2011). We found that olanzap-
ine and risperidone disrupt the CS2 (a less salient condi-
tioned stimulus) avoidance to a greater extent than the 
CS1 avoidance. Although it was not the focus of the cur-
rent study, the preferential action against the CS2 avoid-
ance over the CS1 avoidance by olanzapine and clozap-
ine was also apparent. For example, on the first drug 
test day, the VEH + CLZ rats made 12.5% CS1 avoid-
ance, but only 4.17% CS2 avoidance. Similarly, the 
VEH + OLZ rats made 23% CS1 avoidance but 19% CS2 
avoidance. Another piece of supporting evidence was 
that the impaired CS1 avoidance in the VEH + OLZ 
group recovered completely on the drug-free retraining 
session, while the CS2 avoidance did not. Finally, the re-
versal effect of DOI pretreatment on clozapine-induced 
CS1 disruption lasted longer (2 days) than its effect on 
CS2 disruption (1 day), indirectly reflecting the stron-
ger and preferential action of clozapine against the CS2 
avoidance over the CS1 avoidance. This finding may ex-
plain that antipsychotic drugs achieve their clinical ef-
fects on psychosis by selectively attenuating the motiva-
tional salience of psychotic thoughts and perception (Li 
et al. 2004b, 2007). 
The present study further confirmed the existence 
of a clozapine-induced tolerance effect and an olanzap-
ine-induced sensitization effect in the CAR model. This 
kind of repeated effect is evidenced by the finding that 
the VEH + CLZ rats made significantly more avoid-
ance responses, and the VEH + OLZ rats made signifi-
cantly fewer avoidance responses than the VEH + VEH 
rats in the drug challenge test (Li et al. 2007, 2009a, 2010; 
Mead and Li 2010). Consistent with our previous find-
ings, pretreatment of DOI did not alter both types of re-
peated effects, indicating that the long-term effects of 
clozapine and olanzapine are not mediated by their ac-
tions on the 5-HT2A/2C receptor system. In our previous 
study, we showed that pretreatment of quinpirole atten-
uated olanzapine-induced sensitization effect, but po-
tentiated clozapine-induced tolerance, suggesting that 
the repeated effect of clozapine and olanzapine may be 
commonly mediated by their action on the D2/3 recep-
tor system (Atkins et al. 1999; Kapur et al. 2003; Moran-
Gates et al. 2006). Overall, findings from the previous 
study and the present one collectively revealed dissoci-
ated dopamine and serotonin receptor systems underly-
ing the acute and repeated effects of clozapine and olan-
zapine. One important future project is to delineate the 
neuroadaptive changes induced by repeated antipsy-
chotic treatment that are mediated by these and other 
receptor systems (e.g. 5-HT1A, D1, D4, etc.) and identify 
their clinical relevance. 
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